Alydia
Apr 01, 2021
Amgen to acquire Rodeo for $55M; Novartis expands radioligand portfolio; Organon acquires Alydia for $240M; Forma announces positive FT-4202 dose levels
Amgen to acquire Rodeo Therapeutics for USD 55 Million Upfront Amgen Inc. and Rodeo Therapeutics Corporation announced a deal under which Amgen will take over Rodeo, a privately-held biopharmaceutical company based in Seattle, which develops small-molecule therapies to enhance regeneration and repair of se...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
